#151 Rotavirus Vaccine: A shot to get off the pot(ty)
CLINICAL QUESTION
What are the benefits and risks of the rotavirus vaccine?
BOTTOM LINE
In developed countries, rotavirus vaccine prevents serious diarrhea for one in 22 and reduces hospitalizations for one in 100. There does not appear to be an increase in intussusception rates.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- For monovalent and pentavalent rotavirus vaccine (RV1 and RV5, respectively)
- Systematic Review (RV1: 29 Randomized Controlled Trials (RCTs), 101,671 infants; RV5: 12 RCTs, 84,592 infants), vaccine versus placebo in developed (western) countries.1 Statistically significant results at two years:
- Any rotavirus diarrhea:
- RV1: Relative Risk (RR) 0.33 (95% confidence interval, 0.21-0.50).
- RV5: RR 0.36 (95% confidence interval 0.25-0.50).
- Placebo rate ~9%, vaccine rate ~3%.
- Number Needed to Treat (NNT) ~17, either vaccine.
- Severe rotavirus diarrhea, NNT ~50, either vaccine.
- RV1 (no or too little data from RV5):
- Any diarrhea, NNT ~40.
- Any severe diarrhea, NNT ~22.
- Hospitalizations, NNT ~100.
- Mortality: No difference.
- Limitations: Inconsistent definition of ‘severe diarrhea’ in trials (varies from rotavirus diarrhea scales to hospitalization requiring rehydration therapy).
- Any rotavirus diarrhea:
- Safety:
- Reactions to immunization similar between vaccine and placebo: rates were fever (38-41%), diarrhea (7-25%), vomiting (13-17%).1,2
- No increase in intussusception in RCTs or subsequent surveillance/observational data.1-5
- Systematic Review (RV1: 29 Randomized Controlled Trials (RCTs), 101,671 infants; RV5: 12 RCTs, 84,592 infants), vaccine versus placebo in developed (western) countries.1 Statistically significant results at two years:
- Rotavirus transmission is fecal-oral and fomites (including toys) with a 1-5 day incubation.6
- An estimated 80% of children have rotavirus gastroenteritis by age five.7
- One in 62-312 children are hospitalized for rotavirus.6
- Most (90%) Canadian cases occur December-April and 63% affect children <2 years old.8,9
- Licenced oral vaccines include:
- RV1 (Rotarix®; GlaxoSmithKline): Live attenuated, human monovalent rotavirus, two oral doses (two and four months).
- RV5 (RotaTeq®; Merck): Live human-bovine reassortment, pentavalent rotavirus, three oral doses (two, four, and six months).
- Publicly funded in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Quebec, Prince Edward Island, Northwest Territories, and Yukon.
- Approximately $165-$200 per vaccine series.
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
